Healthcare Opportunities Conference


Roth Inaugural Healthcare Opportunities Conference
October 6th, 2022

The Yale Club, New York City, NY

Roth Capital Partners is pleased to invite you to our Roth Inaugural Healthcare Opportunities Conference to be held at The Yale Club in New York City, NY on October 6th, 2022.

This event will consist of 10 minute Company Presentations introduced by Roth Research Analysts as well as 1-on-1/ small group meetings. This format will provide an opportunity for C-level executives representing public healthcare companies in the Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therapeutics to tell their stories to investors.

The event will be in a 1-on-1 / small group format, consisting of 40 minute management-investor meetings to provide our institutional clients with extensive interaction with executive management to gain in-depth insights into each company. 

The intimate format of the event will allow for meaningful interaction with select company management teams through meetings and many social events throughout the event.

Learn About Roth Inaugural Healthcare Opportunities Participating Companies

Todos Medical Ltd.

Todos Medical Ltd. is an in vitro diagnostics company focused on the development of novel blood tests for the early detection of cancer and neurodegenerative disorders by developing novel blood tests that are reliable, affordable and minimally invasive.

First Wave Biopharma Inc.
(Nasdaq: FWBI)

First Wave BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
First Wave is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties.

Clene Inc.
(Nasdaq: CLNN)

Clene is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function. Their nanotherapeutics target cellular energy impairments that are common to many diseases. Their nanotherapeutic platform enables the creation of clean-surfaced,
catalytically-active nanocrystals for therapeutic use. 

BioRestorative Therapies Inc.
(Nasdaq: BRTX)

BioRestorative Therapies is committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions. Their advances harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively. BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes.

Genenta Science S.p.A.
(Nasdaq: GNTA)

Genenta is a clinical stage immuno oncology-company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors.

Genenta’s lead product candidate, Temferon™, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance.

atai Life Sciences N.V.
(Nasdaq: ATAI)

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. 

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients. 

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit

Stemtech Corp.

Stemtech Corporation is the pioneer stem cell nutrition company, founded in 2005. Stemtech offers all-natural, plant-based anti-aging stem cell nutrition products branded as: RCM System, stemrelease3 ™, Stemflo ® MigraStem, OraStem ® (Oral Health Care), and D-Fuze ™ (EMF blocker) in the U.S. and select international markets through their network marketing model. Products support the release, circulation and migration of the body’s adult stem cells from your own bone marrow.  For information, visit

Biofrontera Inc.
(Nasdaq: BFRI)

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Our vision at Biofrontera Inc. is to be a trusted partner who brings unparalleled therapies and service to patients and healthcare providers in the dermatology community.

Assertio Holdings, Inc.
(Nasdaq: ASRT)

Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients and has a robust portfolio of branded prescription products in three areas: neurology, hospital and pain and inflammation. The Company has grown through business development including licensing, mergers, and acquisitions and is interested in products across all therapeutic areas, including our current focus.

Sernova Corp.

Sernova Corp is a clinical-stage biotechnology company developing regenerative therapeutic technologies to deliver a ‘functional cure’ for chronic diseases, including insulin-dependent diabetes, thyroid disease and rare diseases like hemophilia A. Sernova has developed the Cell-Pouch SystemTM, an implantable, scalable, and retrievable medical device which forms a natural environment in the body for long-term survival and function of immune-protected therapeutic cells that release necessary, but missing proteins or factors to treat chronic diseases.

Helius Medical Technologies, Inc.
(Nasdaq: HSDT)

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information, visit

Roth Inaugural Healthcare Opportunities Conference